[摘要] 目前，肺癌已经成为世界范围内发病率及死亡率最高的肿瘤之一。随着分子生物学研究的飞速进展，肺癌的内科治疗已经从传统的化疗、放疗发展为个性化的靶向治疗。针对多种靶基因突变的靶向治疗为肺癌患者延长生命、提高生活质量带来希望。此文就最新的非小细胞肺癌靶基因EML4-ALK相关问题进行综述。

    [关键词] 肺癌；个性化治疗；基因；EML4-ALK融合基因；表皮生长因子受体

    [中图分类号] R734.2   [文献标识码] A   [文章编号] 2095-0616(2014)09-40-06

    Review of the study of EML4-ALK fusion protein of non-small cell lung cancer

    GAO Jie  WEI Lixin

    Department of Pathology, the General Hospital of PLA, Beijing 100853, China

    [Abstract] Today, lung cancer is the most commonly diagnosed cancer and the leading causes of tumor-related deaths in the world. Along with the fast progress of molecular biology, the traditional treatment methods, chemotherapy and radiotherapy gradually have been development to individual therapy. Strategies to maximize treatment benefit have centered on individualizing treatment according to the molecular profile of the non-small cell lung cancer. This review describes the relative information of the newest oncogenic drivers, EML4-ALK fusion protein, have also been implicated as in the pathogenesis of the non-small cell lung cancer. ......